These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 24909062)

  • 1. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
    Park SW; Jung HH; Heo H
    Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
    [No Abstract]   [Full Text] [Related]  

  • 2. Retinal detachment despite aggressive management of aggressive posterior retinopathy of prematurity.
    Suk KK; Berrocal AM; Murray TG; Rich R; Major JC; Hess D; Johnson RA
    J Pediatr Ophthalmol Strabismus; 2010 Dec; 47 Online():e1-4. PubMed ID: 21175113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral effect of unilateral bevacizumab injection in retinopathy of prematurity.
    Karaca C; Oner AO; Mirza E; Polat OA; Sahiner M
    JAMA Ophthalmol; 2013 Aug; 131(8):1099-101. PubMed ID: 23744183
    [No Abstract]   [Full Text] [Related]  

  • 4. A rare association of intravitreal bevacizumab injection with double ridge formation in retinopathy of prematurity.
    Yaz Y; Erol N; Gursoy H; Basmak H; Bilgec MD
    J Pediatr Ophthalmol Strabismus; 2014 Oct; 51 Online():e66-8. PubMed ID: 25333243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinal fluorescein angiographic changes following intravitreal anti-VEGF therapy.
    Henaine-Berra A; Garcia-Aguirre G; Quiroz-Mercado H; Martinez-Castellanos MA
    J AAPOS; 2014 Apr; 18(2):120-3. PubMed ID: 24698606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
    Lepore D; Quinn GE; Molle F; Baldascino A; Orazi L; Sammartino M; Purcaro V; Giannantonio C; Papacci P; Romagnoli C
    Ophthalmology; 2014 Nov; 121(11):2212-9. PubMed ID: 25001158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effect of antiangiogenic therapy for retinopathy of prematurity up to 5 years of follow-up.
    Martínez-Castellanos MA; Schwartz S; Hernández-Rojas ML; Kon-Jara VA; García-Aguirre G; Guerrero-Naranjo JL; Chan RV; Quiroz-Mercado H
    Retina; 2013 Feb; 33(2):329-38. PubMed ID: 23099498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal macular dimple in retinopathy of prematurity.
    Behera UC; Tripathy D; Singh J
    JAMA Ophthalmol; 2015 Apr; 133(4):e145348. PubMed ID: 25856652
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
    Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
    Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
    [No Abstract]   [Full Text] [Related]  

  • 10. What is the optimal dosage for intravitreal bevacizumab for retinopathy of prematurity?
    Spandau U
    Acta Ophthalmol; 2013 Mar; 91(2):e154. PubMed ID: 22989079
    [No Abstract]   [Full Text] [Related]  

  • 11. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
    Goldman DR; Baumal CR
    J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluorescein angiographic observations of peripheral retinal vessel growth in infants after intravitreal injection of bevacizumab as sole therapy for zone I and posterior zone II retinopathy of prematurity.
    Tahija SG; Hersetyati R; Lam GC; Kusaka S; McMenamin PG
    Br J Ophthalmol; 2014 Apr; 98(4):507-12. PubMed ID: 24403566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
    Harper CA; Wright LM; Young RC; Read SP; Chang EY
    Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early refractive outcome after intravitreous bevacizumab for retinopathy of prematurity.
    Harder BC; von Baltz S; Schlichtenbrede FC; Jonas JB
    Arch Ophthalmol; 2012 Jun; 130(6):800-1. PubMed ID: 22801850
    [No Abstract]   [Full Text] [Related]  

  • 15. Short-term outcome after intravitreal ranibizumab injections for the treatment of retinopathy of prematurity.
    Castellanos MA; Schwartz S; García-Aguirre G; Quiroz-Mercado H
    Br J Ophthalmol; 2013 Jul; 97(7):816-9. PubMed ID: 23221964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
    Erol N; Gürsoy H; Sahin A; Basmak H
    J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal bevacizumab as supplemental treatment or monotherapy for severe retinopathy of prematurity.
    Axer-Siegel R; Snir M; Ron Y; Friling R; Sirota L; Weinberger D
    Retina; 2011; 31(7):1239-47. PubMed ID: 21555969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of intravitreal injection of anti-vascular endothelial growth factor agents for stage 4 retinopathy of prematurity.
    Cheng HC; Lee SM; Hsieh YT; Lin PK
    Retina; 2015 Apr; 35(4):660-6. PubMed ID: 25313709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorescein angiography of recurrent retinopathy of prematurity after initial intravitreous bevacizumab treatment.
    Hoang QV; Kiernan DF; Chau FY; Shapiro MJ; Blair MP
    Arch Ophthalmol; 2010 Aug; 128(8):1080-1. PubMed ID: 20697016
    [No Abstract]   [Full Text] [Related]  

  • 20. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
    Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
    Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.